On February 3, 2025, XTL Biopharmaceuticals Ltd. reported the resignation of directors Tal Klinger and Yair Redl, following a settlement that allows Shareholders to elect one director instead of two. This filing highlights a change in board representation but does not indicate any disagreement with the company management.